Myocardial infarction prevention in patient with angina pectoris and with high gastric ulcer risk

This clinical state involves secondary cardiovascular prophylaxis in patients with symptomatic coronary artery disease presenting as angina pectoris who simultaneously face an elevated susceptibility to gastric mucosal injury and upper gastrointestinal bleeding Although long-term antithrombotic therapies are clinically necessary to prevent acute coronary thrombosis and subsequent myocardial infarction, these interventions impair hemostasis and inhibit mucosal prostaglandins Consequently, individ...

This clinical state involves secondary cardiovascular prophylaxis in patients with symptomatic coronary artery disease presenting as angina pectoris who simultaneously face an elevated susceptibility to gastric mucosal injury and upper gastrointestinal bleeding Angina pectoris reflects underlying myocardial ischemia caused by atherosclerotic plaque accumulation and compromised coronary arterial blood flow Although long-term antithrombotic therapies are clinically necessary to prevent acute coron...

Angina pectoris reflects underlying myocardial ischemia caused by atherosclerotic plaque accumulation and compromised coronary arterial blood flow

Although long-term antithrombotic therapies are clinically necessary to prevent acute coronary thrombosis and subsequent myocardial infarction, these interventions impair hemostasis and inhibit mucosal prostaglandins

Consequently, individuals with pre-existing risk factors—such as advanced age, a history of peptic ulcer disease, or concurrent mucosal irritants—face a heightened risk of developing gastric ulcers and severe gastrointestinal hemorrhage during cardioprotective therapy